Journal of mood and anxiety disorders · 2026
Dose effect of bilateral transcranial magnetic stimulation for depression and anxiety in a real-world clinical setting.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marchuck Noah, DeMoss Raneeka, Turner William C, Tobar Michelle, Hunter Ben W, Rothbaum Alex O, van Rooij Sanne J H
Аннотация
UNLABELLED: Transcranial Magnetic Stimulation (TMS) is a non-invasive intervention for treatment-resistant depression (TRD). Comorbid anxiety is common in TRD patients. We examined the effect of single-dose versus high-dose bilateral TMS on depression and anxiety.
METHODS: Seventy-eight patients received 1 Hz right dorsolateral prefrontal cortex (DLPFC) stimulation combined with left single-dose or high-dose iTBS to the left DLPFC at a nonprofit clinic. Depression and anxiety symptoms were measured at baseline, after 10 and 20 sessions, and final (30-36) TMS sessions.
RESULTS: Bilateral TMS resulted in a significant decrease in depression (F(3,70)= 9.670, p < .001; 74.4% response, 47.7% remission) and anxiety (F(3,70)= 4.916, p = 0.004, 52.6% response, 39.7% remission). The high-dose group showed a faster reduction in depression (F(3,70)= 2.875, p = 0.042), but not anxiety symptoms. There was no dose difference at the final session.
CONCLUSION: Bilateral TMS improved depression and anxiety symptoms with a quicker reduction in depression symptoms with higher dosing, which highlights an important clinical consideration to reduce visits.
METHODS: Seventy-eight patients received 1 Hz right dorsolateral prefrontal cortex (DLPFC) stimulation combined with left single-dose or high-dose iTBS to the left DLPFC at a nonprofit clinic. Depression and anxiety symptoms were measured at baseline, after 10 and 20 sessions, and final (30-36) TMS sessions.
RESULTS: Bilateral TMS resulted in a significant decrease in depression (F(3,70)= 9.670, p < .001; 74.4% response, 47.7% remission) and anxiety (F(3,70)= 4.916, p = 0.004, 52.6% response, 39.7% remission). The high-dose group showed a faster reduction in depression (F(3,70)= 2.875, p = 0.042), but not anxiety symptoms. There was no dose difference at the final session.
CONCLUSION: Bilateral TMS improved depression and anxiety symptoms with a quicker reduction in depression symptoms with higher dosing, which highlights an important clinical consideration to reduce visits.